Neuroblastoma and opsoclonus-myoclonus-ataxia syndrome - Clinical and pathological characteristics

Folia Neuropathologica

Volumn 46, Issue 3, 2008, Pages 176-185

  Stefanowicz, Joanna ^a   Izycka Świeszewska, Ewa ^a   Drozyńska, Elzbieta ^a   Pienczk, Jerzy ^a   Polczyńska, Katarzyna ^a   Czauderna, Piotr ^a   Sierota, Danuta ^a   Bień, Ewa ^a   Stachowicz Stencel, Teresa ^a   Kosiak, Wojciech ^a   Balcerska, Anna ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Clinical outcome; Opsoclonus myoclonus ataxia; Paraneoplastic syndrome; Pathology; Peripheral neuroblastic tumours (pNT)

Indexed keywords

ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HYDROCORTISONE; IFOSFAMIDE; METHISOPRINOL; PREDNISONE; STEROID; TENIPOSIDE; VINCRISTINE;

ABDOMINAL SCINTISCANNING; ADRENAL GLAND; ANXIETY; ARTICLE; ATAXIA; BALANCE IMPAIRMENT; CANCER ADJUVANT THERAPY; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DYSMETRIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; MORNING SICKNESS; MYOCLONUS; NEUROBLASTOMA; NEUROLOGIC DISEASE; NYSTAGMUS; OPSOCLONUS MYOCLONUS SYNDROME; PRESCHOOL CHILD; TUMOR LOCALIZATION; TUMOR VOLUME; UPPER RESPIRATORY TRACT INFECTION; VACCINATION REACTION; VIRUS INFECTION;

EID: 55349119860     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, Dalmau J. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003; 53: 347-353.
2. Beck S, Fuhlhuber V, Krasenbrink I, Tschernatsch M, Kneifel N, Kirsten A, Jaeger C, Kaps M, Preissner KT, Lang B, Rostasy K, Blaes F. IgG subclass distribution of autoantibodies in pediatric opsoclonus-myoclonus syndrome. J Neuroimmunol 2007; 185: 145-149.
3. Blaes F. Immunotherapeutic approaches to paraneoplastic neurological disorders. Exp Opin Biol Ther 2002; 2: 419-430.
4. Blaes F, Fuhlhuber V, Korfei M, Tschernatsch M, Behnisch W, Rostasy K, Hero B, Kaps M, Preissner KT. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 2005; 58: 313-317.
5. Cohn SL, Salven H, Herst CV, Maurer HS, Nieder ML, Morgan ER, Rosen ST. Single copies of the N-myc oncogene in neuroblastomas from children presenting with the syndrome of opsoclonusmyoclonus. Cancer 1988; 62: 723-726.
6. Cooper R, Khakoo Y, Matthay KK, Lukens JN, Seeger RC, Stram DO, Gerbing RB, Nakagawa A, Shimada H. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features - a report from the Children's Cancer Group. Med Pediatr Oncol 2001; 36: 623-629.
7. Dambska M, Laure-Kamionowska M. Brain damage in children in course of neoplastic diseases. Folia Neuropathol 1999; 37: 133-137.
8. Darnell RB. Paraneoplastic neurologic disorders. Arch Neurol 2004; 61: 30-32.
9. Dziewulska D, Drac H, Michej W, Mieszkowski J, Rafalowska J. Paraneoplastic syndrome in the course of lung adenocarcinoma: morphological picture and immunohistochemical analysis of the inflammatory in filtrates and PECAM-1 expression. Folia Neuropathol 2000; 38: 29-33.
10. Gambini C, Conte M, Bernini G, Angelini P, Pession A, Paolucci P, Donfrancesco A, Veneselli, Mazzocco K, Tonini G, Raffaghello L, Dominici C, Morando A, Negri F, Favre A, De Bernardi B, Pistoia V. Neuroblastic tumors associated with opsoclonusus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Arch 2003; 442: 555-562.
11. Graus F, Dalmau J. Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol 2007; 20: 732-737.
12. Hayward K, Jeremy RJ, Jenkins S, Barkowich AJ, Gultekin SH, Kramer J, Crittenden M, Matthay K. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome:relationship to MRI. ndings and antineuronal antibodies. J Pediatr 2001; 139: 552-559.
13. Honnorat J, Antoine J-C. Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2007; 2: 22.
14. Izycka-Swieszewska E, Stefanowicz J, Adamkiewicz-Drozynska E, Pienczk J, Rzepko R. Kinsbourne's encephalopathy six years before the diagnosis of adrenal ganglioneuroma. Aktualn Neurol 2005; 2: 152-156.
15. Kaluza J, Slowinski J, Bujny T, Grochala M. Paraneoplastic syndrome simulating encephalitis in the course of testicular seminoma. Folia Neuropathol 1997; 35: 24-28.
16. Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psych 1962; 25: 271-279.
17. Klein A, Schmitt B, Boltshauser E. Long-term outcome of ten children with opsoclonus-myoclonus syndrome. Eur J Pediatr 2007; 166: 359-363.
18. Kushner B, Cohn S, Matthay K. Treatment of Neuroblastoma. In: Cheung N-K, Cohn S (eds.). Neuroblastoma. Springer-Verlag, Berlin Heidelberg 2005; pp. 123-131.
19. Levisohn L, Cronin-Golomb A, Schmahmann JD. Neuropsychogical consequences of cerebellar tumour resection in children:cerebellar cognitive affective syndrome in a paediatric population. Brain 2000; 123: 1041-1050.
20. Plantaz D, Michon J, Valteau-Couanet D, Coze C, Chastagner P, Bergeron C, Nelken B, Martelli H, Peyroulet MC, Carpentier AF, Armari-Alla C, Pagnier A, Rubie H. Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma Longterm survival. Study of the French Society of Pediatric Oncologists. Arch Pediatr 2000; 7: 621-628.
21. Pranzattelli MR. The neurobiology of opsoclonus-myoclonus. Clin Neuropharmacol 1992; 15: 186-228.
22. Pranzatelli MR, Hyland K, Tate ED, Arnold LA, Allison TJ, Soori GS (2004) Evidence of cellular immune activation in children with opsoclonus-myoclonus: cerebrospinal fluid neopterin. J Child Neurol 2004; 19: 919-924.
23. Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Lee ND, Fisher J, Jasty R. Immunophenotype of blood lymphocytes in neuroblastoma-associated opsoclonus-myoclonus. J Pediatr Hematol Oncol 2004; 26: 718-723.
24. Ramos S, Temudo T. Opsoclonus myoclonus syndrome: how long are we going to go on researching? Rev Neurol 2002; 35: 322-325.
25. Roberts W, Darnell RB. Neuroimmunology of the paraneoplastic neurological degenerations. Curr Opin Immunol 2004; 16: 616-622.
26. Rudnick E, Khakoo Y, Antunes NL, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Matthay KK. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001; 36: 612-622.
27. Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997; 28: 284-288.
28. Shimada H, Ambros I. Pathology of peripheral neuroblastic tumors. In: Cheung N-K, Cohn S (eds.). Neuroblastoma. Springer-Verlag, Berlin Heidelberg 2005; pp. 87-95.
29. SIOP Protocol. Treatment of children over the age of 1 year with unresectable localised neuroblastoma without MYCN amplification. 2000.
30. Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiological trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs 2005; 22: 8-19.
31. Telander RL, Smihson WA, Groover R. Clinical outcome in children with acute cerebellar ecephalopathy and neuroblastoma. J Pediatr Surg 1989; 24: 11-14.